MemphasysASX:MEM +14.29% Receivables Turnover is 0.10 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Memphasys ranks worse than 99.01% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Memphasys's Revenue for the
six
months ended in Dec. 2025 was A$0.01 Mil. Memphasys's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.12 Mil.
Hence, Memphasys's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.10.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Memphasys Receivables Turnover Related Terms
Memphasys Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Memphasys's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MEM vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Memphasys's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Memphasys Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Memphasys's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Memphasys's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Memphasys (ASX:MEM) has a Receivables Turnover of 0.10 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Memphasys and its competitors. According to the industry distribution chart, Memphasys ranks #803 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 99%.
Is Memphasys' Receivables Turnover too high?
Memphasys' current Receivables Turnover is 0.10. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Memphasys' value of 0.10 is 98.2% below this industry median. Based on the distribution chart, Memphasys ranks #803 out of 811 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Memphasys' Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Memphasys ranks #803 out of 811 companies for Receivables Turnover. This places Memphasys in the lower half of its industry. The industry median Receivables Turnover is 5.51. Memphasys' value of 0.10 is 98.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Memphasys's current Receivables Turnover of 0.10 is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Memphasys and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Memphasys's current Receivables Turnover is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Memphasys stock overvalued right now?
Memphasys (ASX:MEM) has a current Receivables Turnover of 0.10. The current Receivables Turnover is 0.10 and 98.2% below the Medical Devices & Instruments industry median of 5.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Memphasys (ASX:MEM), the current Receivables Turnover is 0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MEM has been successfully added to your 